In vitro activity of tigecycline and other tetracyclines against carbapenem-resistant acinetobacter species: Report from a tertiary care centre in Karachi, Pakistan

Chemotherapy

Volumn 56, Issue 3, 2010, Pages 184-189

  Shakoor, Sadia ^a   Khan, Erum ^a   Zafar, Afia ^a   Hasan, Rumina ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Acinetobacter; Carbapenem resistance; Karachi; Susceptibility breakpoints; Tigecycline

Indexed keywords

CARBAPENEM; DOXYCYCLINE; MINOCYCLINE; TETRACYCLINE; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER INFECTION; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HOSPITAL INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PAKISTAN; PRIORITY JOURNAL; TERTIARY HEALTH CARE;

ACINETOBACTER; ACINETOBACTER INFECTIONS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PAKISTAN; TETRACYCLINES;

EID: 77953334379     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316328     Document Type: Article

References (22)

1. Villegas MV, Hartstein AI: Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24: 284-295.
2. Traub WH, Geipel U, Schwarze I, Bauer D: A cluster of nosocomial cross-infections due to multiple antibiotic-resistant Acinetobacter baumannii : characterization of the strain and antibiotic susceptibility studies. Chemotherapy 1999; 45: 349-359.
3. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG: Bad bugs need drugs: an update on development pipeline from the antimicrobial availability taskforce of the Infectious Disease Society of America. Clin Infect Dis 2006; 42: 657-668. (Pubitemid 43271379)
4. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-208.
5. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, Llanos AC, Pachón J: Activity of Tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-4481.
6. Navon-Venezia S, Leavitt A, Carmeli Y: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii . J Antimicrob Chemother 2007; 59: 772-774.
7. Ahmed A, Zafar A, Mirza S: Antimicrobial activity of tigecycline against nosocomial pathogens in Pakistan: a multicentre study. J Pak Med Assoc 2009; 59: 240-242.
8. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Approved standard, CLSI document M100-S19. 2009.
9. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME: Tigecycline for the treatment of multi-drug resistant (including carbapenem- resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62: 895-904.
10. Seifert H, Stefanik D, Wisplinghoff H: Comparative in vitro activities of tigecycline and other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58: 1099-1100.
11. Draghi DC, Tench S, Dowzicky MJ, Sahm DF: Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008; 54: 91-100.
12. Canigia LF, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C; Argentinean Tigecycline Surveillance Group: Multicentre study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy 2009; 55: 20-27.
13. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E: Clinical and microbiological outcomes of serious infections with multidrug-resistant gram negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-570.
14. British Society for Antimicrobial Chemotherapy: Susceptibility testing: breakpoints. 2009. www.bsac.org.uk/susceptibility-testing/ breakpoints.cfm
15. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL: Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59: 128-131.
16. Fernandez-Mazarrasa C, Mazarrasa O, Calvo J, del Arco A, Martinez-Martinez L: High concentrations of manganese in Mueller Hinton agar increase MICs of tigecycline determined by Etest. J Clin Microbiol 2009; 47: 827-829.
17. Casal M, Rodriguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, Tenorio A, Gimenez MJ, Bartolome R, Garcia-Rey C, Aguilar L, Garcia-Escribano L: Influence of testing methodology on the tigecycline activity profile against presumably tigecycline- non-susceptible Acinetobacter spp. J Antimicrob Chemother 2009; 64: 69-72.
18. Curcio D, Fernandez F: Tigecycline for Acinetobacter baumannii infections: other considerations. Clin Infect Dis 2008; 46: 1797-1798.
19. Bolmstrom A, Karlsson A, Engelhardt A, Ho P, Petersen PJ, Bradford PA, Jones CH: Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 2007; 45: 2474-2479.
20. Capone A, DArezzo S, Visca P, Petrosillo N: In vitro activity of tigecycline against multidrug resistant Acinetobacter baumannii . J Antimicrob Chemother 2008; 62: 422-425.
21. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC: Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med 2003; 29: 2072-2076.
22. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA: In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or resistant Acinetobacter baumannii . Antimicrob Agents Chemother 2007; 51: 1621-1626.